Title | Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. |
Publication Type | Journal Article |
Year of Publication | 2017 |
Authors | Staunton L, Tonry C, Lis R, Espina V, Liotta L, Inzitari R, Bowden M, Fabre A, O'Leary J, Finn SP, Loda M, Pennington SR |
Journal | Mol Cancer Res |
Volume | 15 |
Issue | 3 |
Pagination | 281-293 |
Date Published | 2017 03 |
ISSN | 1557-3125 |
Keywords | Chromatography, Liquid, Datasets as Topic, Gene Expression Profiling, Humans, Male, Mass Spectrometry, Neoplasm Grading, Neoplasm Proteins, Prostatic Neoplasms, Proteomics, Tumor Microenvironment |
Abstract | Prostate cancer is the second most common cancer in men worldwide. Gleason grading is an important predictor of prostate cancer outcomes and is influential in determining patient treatment options. Clinical decisions based on a Gleason score of 7 are difficult as the prognosis for individuals diagnosed with Gleason 4+3 cancer is much worse than for those diagnosed with Gleason 3+4 cancer. Laser capture microdissection (LCM) is a highly precise method to isolate specific cell populations or discrete microregions from tissues. This report undertook a detailed molecular characterization of the tumor microenvironment in prostate cancer to define the proteome in the epithelial and stromal regions from tumor foci of Gleason grades 3 and 4. Tissue regions of interest were isolated from several Gleason 3+3 and Gleason 4+4 tumors using telepathology to leverage specialized pathology expertise to support LCM. Over 2,000 proteins were identified following liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of all regions of interest. Statistical analysis revealed significant differences in protein expression (>100 proteins) between Gleason 3 and Gleason 4 regions-in both stromal and epithelial compartments. A subset of these proteins has had prior strong association with prostate cancer, thereby providing evidence for the authenticity of the approach. Finally, validation of these proteins by immunohistochemistry has been obtained using an independent cohort of prostate cancer tumor specimens. This unbiased strategy provides a strong foundation for the development of biomarker protein panels with significant diagnostic and prognostic potential. . |
DOI | 10.1158/1541-7786.MCR-16-0358 |
Alternate Journal | Mol Cancer Res |
PubMed ID | 28057717 |
Grant List | R21 AR061075 / AR / NIAMS NIH HHS / United States R21 CA125698 / CA / NCI NIH HHS / United States R21 CA177535 / CA / NCI NIH HHS / United States R33 CA157403 / CA / NCI NIH HHS / United States |
Related Faculty:
Massimo Loda, M.D.